|
KMID : 1001020130110020052
|
|
Korean Journal of Urological Oncology
2013 Volume.11 No. 2 p.52 ~ p.62
|
|
|
What Is the Optimal Strategy to Achieve Long Term Survival in mRCC
|
|
Choi Don-Kyoung
Seo Seong-Il
|
|
|
Abstract
|
|
|
|
Recent developments in the treatment of metastatic renal cell carcinoma (mRCC) will be discussed, with emphasis on data published over the past year. With recent improvements in the prognosis for patients with metastatic renal cell carcinoma (mRCC), focus is now shifting towards maximizing clinical benefit from targeted therapies. To achieve this goal, a number of factors which impact on treatment selection and outcomes need to be considered when treating patients with mRCC, such as the optimal sequence of targeted therapies. Futhermore, despite the absence of data from Phase III trials, available evidence suggests that some patients may benefit substantially from cytoreductive nephrectomy (CRN) in the era of targeted therapy. Results of ongoing and planned clinical trials, coupled with advances in the understanding of the underlying biology of RCC, are likely to contribute towards even greater improvements in the prognosis for patients with mRCC in the near future. The purpose of this review is to analyze and weigh the efficacy data available for the drugs approved for metastatic renal cell carcinoma and to suggest the best therapy based on the multiplicity of features of each patient in relation to the main characteristics of each agent.
|
|
|
KEYWORD
|
|
|
Rcc, Target therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|